WO1998007855A2 - Proteines secretees et polynucleotides les codant - Google Patents

Proteines secretees et polynucleotides les codant Download PDF

Info

Publication number
WO1998007855A2
WO1998007855A2 PCT/US1997/014641 US9714641W WO9807855A2 WO 1998007855 A2 WO1998007855 A2 WO 1998007855A2 US 9714641 W US9714641 W US 9714641W WO 9807855 A2 WO9807855 A2 WO 9807855A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
polynucleotide
seq
sequence
clone
Prior art date
Application number
PCT/US1997/014641
Other languages
English (en)
Other versions
WO1998007855A3 (fr
Inventor
Kenneth Jacobs
John M. Mccoy
Edward R. Lavallie
Lisa A. Racie
David Merberg
Maurice Treacy
Vikki Spaulding
Original Assignee
Genetics Institute, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute, Inc. filed Critical Genetics Institute, Inc.
Priority to JP10510922A priority Critical patent/JP2000516816A/ja
Priority to EP97937331A priority patent/EP0922100A2/fr
Priority to CA002263192A priority patent/CA2263192A1/fr
Priority to AU39864/97A priority patent/AU3986497A/en
Publication of WO1998007855A2 publication Critical patent/WO1998007855A2/fr
Publication of WO1998007855A3 publication Critical patent/WO1998007855A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins
  • the present invention provides a composition comp ⁇ sing an isolated polynucleotide selected from the group consisting of
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1 from nucleotide 27 to nucleotide 413; the nucleotide sequence of SEQ ID NO: l from nucleotide 129 to nucleotide 413; the nucleotide sequence of the full length protein coding sequence of clone AM349_2 deposited under accession number ATCC 98155; or the nucleotide sequence of the mature protein coding sequence of clone AM349_2 deposited under accession number ATCC 98155.
  • the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone AM349_2 deposited under accession number ATCC 98155.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • AM349_2 deposited under accession number ATCC 98155, the protein being substantially free from other mammalian proteins
  • the protein comprises the am o acid sequence of SEQ ID NO 2
  • isolate AM349_1 deposited under accession number ATCC
  • 98140 may be substituted for AM349_2 in any of the foregoing
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of
  • such polynucleotide compnses the nucleotide sequence of SEQ ID NO 5 from nucleotide 189 to nucleotide 389, the nucleotide sequence of the full length protein coding sequence of clone AR310_3 deposited under accession number ATCC 98155, or the nucleotide sequence of the mature protein coding sequence of clone AR310_3 deposited under accession number ATCC 98155
  • the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone AR 10_3 deposited under accession number ATCC 98155.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • AR310_3 deposited under accession number ATCC 98155; the protein being substantially free from other mammalian proteins.
  • the protein comprises the amino acid sequence of SEQ ID NO:6.
  • isolate AR310_2 deposited under accession number ATCC 98140 may be substituted for AR310_3 in any of the foregoing.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:8 from nucleotide 448 to nucleotide 603; the nucleotide sequence of SEQ ID NO:8 from nucleotide 547 to nucleotide 603; the nucleotide sequence of the full length protein coding sequence of clone AS 186_3 deposited under accession number ATCC 98155; or the nucleotide sequence of the mature protein coding sequence of clone AS186_3 deposited under accession number ATCC 98155.
  • the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone AS 186_3 deposited under accession number ATCC 98155.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO: 1
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:9;
  • isolate AS186_2 deposited under accession number ATCC 98140 may be substituted for AS 186_3 in any of the foregoing.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide composes the nucleotide sequence of SEQ ID NO.1 1 from nucleotide 207 to nucleotide 533, the nucleotide sequence of SEQ ID NO 1 1 from nucleotide 252 to nucleotide 533; the nucleotide sequence of the full length protein coding sequence of clone AY160_2 deposited under accession number ATCC 98155, or the nucleotide sequence of the mature protein coding sequence of clone AY 160_2 deposited under accession number ATCC 98155.
  • the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone AY160_2 deposited under accession number ATCC 98155
  • the present invention provides a composition composing a protein, wherein said protein composes an ammo acid sequence selected from the group consisting of
  • isolate AY160_1 deposited under accession number ATCC 98140 may be substituted for AY160_2 in any of the foregoing.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • polynucleotide which encodes a species homologue of the protein of (g) or (h) above .
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 14 from nucleotide 84 to nucleotide 548; the nucleotide sequence of the full length protein coding sequence of clone BDI27_16 deposited under accession number ATCC 98155; or the nucleotide sequence of the mature protein coding sequence of clone BD127_16 deposited under accession number ATCC 98155.
  • the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone BD127_16 deposited under accession number ATCC 98155.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ ID NO 14 or SEQ ID NO
  • the present invention provides a composition compnsing a protein, wherein said protein composes an amino acid sequence selected from the group consisting of
  • isolate BD 127_ 1 1 deposited under accession number ATCC 98140 may be substituted for BD127_16 in any of the foregoing
  • the present invention provides a composition composing an isolated polynucleotide selected from the group consisting of
  • such polynucleotide composes the nucleotide sequence of SEQ ID NO: 18 from nucleotide 51 to nucleotide 598; the nucleotide sequence of the full length protein coding sequence of clone BL205_14 deposited under accession number ATCC 98155, or the nucleotide sequence of the mature protein coding sequence of clone BL205_14 deposited under accession number ATCC 98155
  • the polynucleotide encodes the full length or mature protein encoded by the cDNA insert of clone BL205_14 deposited under accession number ATCC 98155
  • the present invention provides a polynucleotide encoding a protein composing the amino acid sequence of SEQ ID NO 19 from amino acid 84 to amino acid 182
  • the present invention provides a composition composing a protein, wherein said protein composes an amino acid sequence selected from the group consisting of.
  • isolate BL205_7 deposited under accession number ATCC 98140 may be substituted for BL205_14 in any of the foregoing.
  • the polynucleotide is operably linked to an expression control sequence.
  • the invention also provides a host cell, including bacteoal, yeast, insect and mammalian cells, transformed with such polynucleotide compositions
  • Processes are also provided for producing a protein, which comprise *
  • Protein compositions of the present invention may further comprise a pharmaceutically acceptable comer Compositions composing an antibody which specifically reacts with such protein are also provided by the present invention
  • Methods are also provided for preventing, treating or ameliorating a medical condition which composes administeong to a mammalian subject a therapeutically effective amount of a composition composing a protein of the present invention and a pharmaceutically acceptable earner
  • nucleotide and amino acid sequences are reported below for each clone and protein disclosed in the present application In some instances the sequences are preliminary and may include some incorrect or ambiguous bases or ammo acids
  • the actual nucleotide sequence of each clone can readily be determined by sequencing of the deposited clone in accordance with known methods The predicted amino acid sequence (both full length and mature) can then be determined from such nucleotide sequence
  • the amino acid sequence of the protein encoded by a particular clone can also be determined by expression of the clone in a suitable host cell, collecting the protein and determining its sequence
  • reported protein sequences include "Xaa” designators These "Xaa” designators indicate either ( 1 ) a residue which cannot be identified because of nucleotide sequence ambiguity or (2) a stop codon in the determined nucleotide sequence where applicants believe one should not exist (if the nucleotide sequence were determined more accurately)
  • a "secreted” protein is one which, when expressed in a suitable host cell, is transported across or through a membrane, including transport as a result of signal sequences in its amino acid sequence
  • "Secreted” proteins include without limitation proteins secreted wholly (e g , soluble proteins) or partially (e g , receptors) from the cell in which they are expressed
  • "Secreted” proteins also include without limitation proteins which are transported across the membrane of the endoplpasmic reticulum Clone "AM349 2"
  • a polynucleotide of the present invention has been identified as clone "AM349_2"
  • AM349_2 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins
  • AM349_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AM349_2 protein")
  • nucleotide sequence of the 5' portion of AM349_2 as presently determined is reported in SEQ ID NO 1 What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO 2
  • the predicted acid sequence of the AM349_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO 2
  • Amino acids 1 to 34 are the predicted leader/signal sequence, with the predicted mature ammo acid sequence beginning at ammo acid 35
  • Additional nucleotide sequence from the 3 portion of AM349_2, including the polyA tail, is reported in SEQ ID NO 3
  • the EcoRI/Notl restoction fragment obtainable from the deposit containing clone AM349_2 should be approximately 3450 bp
  • AM349_2 demonstrated at least some identity with a ESTs identified as "zd84d09 rl Soares fetal heart NbHH19W Homo sapiens cDNA" (W81648, BlastN) and "yl72el0 si Homo sapiens cDNA 43276 3'" (H06061 , BlastN) Based upon identity, AM349_2 proteins and each identical protein or peptide may share at least some activity
  • AR310_3 A polynucleotide of the present invention has been identified as clone "AR310_3" AR310_3 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins AR310_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AR310_3 protein")
  • nucleotide sequence of the 5' portion of AR310_3 as presently determined is reported in SEQ ID NO:4.
  • An additional internal nucleotide sequence from AR310_3 as presently determined is reported in SEQ ID NO.5 What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO 6.
  • Additional nucleotide sequence from the 3' portion of AR310_3, including the polyA tail, is reported in SEQ ID NO.7.
  • AR310_3 The nucleotide sequence disclosed herein for AR310_3 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols AR310_3 demonstrated at least some identity with ESTs identified as "yy20b01.sl Homo sapiens cDNA clone 271753 3'" (N35123, BlastN) and "yy33f03.sl Homo sapiens cDNA clone 273053 3'" (N36408, BlastN). Based upon identity, AR310_3 proteins and each identical protein or peptide may share at least some activity
  • AS186_3 A polynucleotide of the present invention has been identified as clone "AS186_3"
  • AS186_3 was isolated from a human fetal brain cDNA library using methods which are selective for cDNAs encoding secreted proteins.
  • AS 186_3 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AS 186_3 protein”)
  • nucleotide sequence of the 5' portion of AS186_3 as presently determined is reported in SEQ ID NO:8. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO:9.
  • the predicted acid sequence of the AS 186_3 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:9
  • Amino acids 1 to 33 are the predicted leader/signal sequence, with the predicted mature ammo acid sequence beginning at amino acid 34. Additional nucleotide sequence from the 3' portion of AS186_3, including the polyA tail, is reported in SEQ ID NO: 10.
  • nucleotide sequence disclosed herein for AS186_3 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols No hits were found in the database.
  • a polynucleotide of the present invention has been identified as clone "AY160_2" AY160_2 was isolated from a human adult retina cDNA library using methods which are selective for cDNAs encoding secreted proteins.
  • AYl 60_2 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "AYl 60_2 protein")
  • SEQ ID NO: 1 The nucleotide sequence of the 5' portion of AY160_2 as presently determined is reported in SEQ ID NO: 1 1. What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO: 12
  • the predicted acid sequence of the AY160_2 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO:
  • Ammo acids 1 to 15 are the predicted leader/signal sequence, with the predicted mature amino acid sequence beginning at amino acid 16. Additional nucleotide sequence from the 3' portion of AY160_2, including the polyA tail, is reported in SEQ ID NO: 13
  • AY160_2 The nucleotide sequence disclosed herein for AY160_2 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. AY160_2 demonstrated at least some identity with an EST identified as "yz84hl 2 rl Homo sapiens cDNA clone 289799 5"' (N77069, BlastN) Based upon identity, AYl 60_2 proteins and each identical protein or peptide may share at least some activity
  • BD127_16 A polynucleotide of the present invention has been identified as clone "BD127_16"
  • BD127_16 was isolated from a human fetal kidney cDNA library using methods which are selective for cDNAs encoding secreted proteins
  • BD 127_ 16 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BD127_16 protein”)
  • nucleotide sequence of the 5' portion of BD127_16 as presently determined is reported in SEQ ID NO 14 What applicants presently believe is the proper reading frame for the coding region is indicated in SEQ ID NO 15
  • the predicted acid sequence of the BD127_16 protein corresponding to the foregoing nucleotide sequence is reported in SEQ ID NO 15
  • Additional nucleotide sequence from the 3' portion of BD127_16, including the polyA tail, is reported in SEQ ID NO 16
  • the EcoRI Notl restoction fragment obtainable from the deposit containing clone BD127_16 should be approximately 1080 bp
  • nucleotide sequence disclosed herein for BD127_16 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols No hits were found in the database
  • a polynucleotide of the present invention has been identified as clone "BL205_14"
  • BL205_14 was isolated from a human adult testes cDNA library using methods which are selective for cDNAs encoding secreted proteins
  • BL205_14 is a full-length clone, including the entire coding sequence of a secreted protein (also referred to herein as "BL205_14 protein")
  • nucleotide sequence of the 5' portion of BL205_14 as presently determined is reported in SEQ ID NO.17
  • An additional internal nucleotide sequence from BL205_14 as presently determined is reported in SEQ ID NO 18 What applicants believe is the proper reading frame and the predicted amino acid sequence encoded by such internal sequence is reported in SEQ ID NO 19.
  • Additional nucleotide sequence from the 3' portion of BL205_14, including the polyA tail, is reported in SEQ ID NO'20
  • the nucleotide sequence disclosed herein for BL205_14 was searched against the GenBank database using BLASTA/BLASTX and FASTA search protocols. No hits were found in the database.
  • Clones AM349_2, AR310_3, AS186_3, AY160_2, BD127 6 and BL205 4 were deposited with the American Type Culture Collection on August 23, 1996 under accession number 98155, from which each clone comprising a particular polynucleotide is obtainable.
  • An additional isolate of each clone was deposited on August 14, 1996 with the American Type Culture Collection under accession number ATCC 98140.
  • Each clone has been transfected into separate bacterial cells (£'. coli) in this composite deposit.
  • Each clone can be removed from the vector in which it was deposited by performing an EcoRl/Notl digestion (5' cite, EcoRI; 3' cite, Notl) to produce the appropriate fragment for such clone (approximate clone size fragment are identified above).
  • Bacterial cells containing a particular clone can be obtained from the composite deposit as follows:
  • oligonucleotide probe or probes should be designed to the sequence that is known for that particular clone. This sequence can be derived from the sequences provided herein, or from a combination of those sequences. The sequence of the oligonucleotide probe that was used to isolate each full-length clone is identified below, and should be most reliable in isolating the clone of interest.
  • the oligonucleotide should preferably be labeled with g- 2 P ATP (specific activity 6000 Ci/mmole) and T4 polynucleotide kinase using commonly employed techniques for labeling oligonucleotides Other labeling techniques can also be used Unincorporated label should preferably be removed by gel filtration chromatography or other established methods The amount of radioactivity incorporated into the probe should be quantitated by measurement in a scintillation counter Preferably, specific activity of the resulting probe should be approximately 4e+6 dpm/pmole
  • the bacteoal culture containing the pool of full-length clones should preferably be thawed and 100 ⁇ l of the stock used to inoculate a steole culture flask containing 25 ml of ste ⁇ le L-broth containing ampicillin at 100 ⁇ g/ml
  • the culture should preferably be grown to saturation at 37°C, and the saturated culture should preferably be diluted in fresh L-broth Aliquots of these dilutions should preferably be plated to determine the dilution and volume which will yield approximately 5000 distinct and well-separated colonies on solid bacte ⁇ ological media containing L-broth containing ampicillin at 100 ⁇ g/ml and agar at 1 5% in a 150 mm peto dish when grown overnight at 37°C Other known methods of obtaining distinct, well-separated colonies can also be employed
  • Standard colony hybodization procedures should then be used to transfer the colonies to nitrocellulose filters and lyse, denature and bake them
  • the filter is then preferably incubated at 65°C for 1 hour with gentle agitation in 6X SSC (20X stock is 175 3 g NaCl/hter, 88 2 g Na citrate liter, adjusted to pH 7 0 with NaOH) containing 0 5% SDS, 100 ⁇ g/ml of yeast RNA, and 10 mM EDTA (approximately lO mL per 150 mm filter)
  • the probe is then added to the hybodization mix at a concentration greater than or equal to le+6 dpm/mL
  • the filter is then preferably incubated at 65°C with gentle agitation overnight
  • the filter is then preferably washed in 500 mL of 2X SSC/0 5% SDS at room temperature without agitation, preferably followed by 500 mL of 2X SSC/0 1 %
  • Fragments of the proteins of the present invention which are capable of exhibiting biological activity are also encompassed by the present invention. Fragments of the protein may be in linear form or they may be cyclized using known methods, for example, as described in H.U. Saragovi, et al., Bio/Technology K), 773-778 (1992) and in R.S. McDowell, et al., J.
  • fragments may be fused to carrier molecules such as immunoglobulins for many purposes, including increasing the valency of protein binding sites.
  • fragments of the protein may be fused through "linker" sequences to the Fc portion of an immunoglobulin.
  • linker For a bivalent form of the protein, such a fusion could be to the Fc portion of an IgG molecule.
  • Other immunoglobulin isotypes may also be used to generate such fusions.
  • a protein - IgM fusion would generate a decavalent form of the protein of the invention.
  • the present invention also provides both full-length and mature forms of the disclosed proteins.
  • the full-length form of the such proteins is identified in the sequence listing by translation of the nucleotide sequence of each disclosed clone.
  • the mature form of such protein may be obtained by expression of the disclosed full-length polynucleotide (preferably those deposited with ATCC) in a suitable mammalian cell or other host cell.
  • the sequence of the mature form of the protein may also be determinable from the amino acid sequence of the full-length form.
  • the present invention also provides genes corresponding to the cDNA sequences disclosed herein.
  • the corresponding genes can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include the preparation of probes or primers from the disclosed sequence information for identification and/or amplification of genes in appropriate genomic libraries or other sources of genomic materials.
  • the present invention also provides for soluble forms of such protein.
  • the intracellular and transmembrane domains of the protein are deleted such that the protein is fully secreted from the cell in which it is expressed.
  • the intracellular and transmembrane domains of proteins of the invention can be identified in accordance with known techniques for determination of such domains from sequence information.
  • Species homologs of the disclosed polynucleotides and proteins are also provided by the present invention. Species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source from the desired species.
  • the invention also encompasses allelic variants of the disclosed polynucleotides or proteins; that is, naturally-occurring alternative foons of the isolated polynucleotide which also encode proteins which are identical, homologous or related to that encoded by the polynucleotides .
  • the isolated polynucleotide of the invention may be operably linked to an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al.. Nucleic Acids Res. 19, 4485-4490 (1991 ), in order to produce the protein recombinantly.
  • an expression control sequence such as the pMT2 or pED expression vectors disclosed in Kaufman et al.. Nucleic Acids Res. 19, 4485-4490 (1991 ), in order to produce the protein recombinantly.
  • Many suitable expression control sequences are known in the art. General methods of expressing recombinant proteins are also known and are exemplified in R. Kaufman, Methods in Enzymology 185, 537-566 (1990).
  • operably linked means that the isolated polynucleotide of the invention and an expression control sequence are situated within a vector or cell in such a way that the protein is expressed by a host cell which has been transformed (transfected) with the ligated polynucleotide/expression control sequence.
  • Mammalian host cells include, for example, monkey COS cells, Chinese Hamster Ovary (CHO) cells, human kidney 293 cells, human epidermal A431 cells, human Colo205 cells, 3T3 cells, CV-1 cells, other transformed primate cell lines, normal diploid cells, cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL- 60, U937, HaK or Jurkat cells.
  • monkey COS cells Chinese Hamster Ovary (CHO) cells
  • human kidney 293 cells human epidermal A431 cells
  • human Colo205 cells human Colo205 cells
  • CV-1 cells other transformed primate cell lines
  • normal diploid cells cell strains derived from in vitro culture of primary tissue, primary explants, HeLa cells, mouse L cells, BHK, HL- 60, U937, HaK or Jurkat cells.
  • yeast eukaryotes
  • prokaryotes such as bacteria.
  • yeast strains include Saccharomyces cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains, Candida, or any yeast strain capable of expressing heterologous proteins.
  • Potentially suitable bacterial strains include Escherichia coli, Bacillus s btilis. Salmonella typhimurium, or any bacterial strain capable of expressing heterologous proteins. If the protein is made in yeast or bacteria, it may be necessary to modify the protein produced therein, for example by phosphorylation or glycosylation of the appropriate sites, in order to obtain the functional protein. Such covalent attachments may be accomplished using known chemical or enzymatic methods.
  • the protein may also be produced by operably linking the isolated polynucleotide of the invention to suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
  • suitable control sequences in one or more insect expression vectors, and employing an insect expression system.
  • Materials and methods for baculovirus/insect cell expression systems are commercially available in kit form from, e.g., Invitrogen, San Diego, California, U.S.A. (the MaxBac® kit), and such methods are well known in the art, as described in Summers and Smith, Texas Agricultural Experiment Station Bulletin No. 1555 (1987), incorporated herein by reference.
  • an insect cell capable of expressing a polynucleotide of the present invention is "transformed.”
  • the protein of the invention may be prepared by culturing transformed host cells under culture conditions suitable to express the recombinant protein.
  • the resulting expressed protein may then be purified from such culture (i.e., from culture medium or cell extracts) using known purification processes, such as gel filtration and ion exchange chromatography.
  • the purification of the protein may also include an affinity column containing agents which will bind to the protein; one or more column steps over such affinity resins as concanavalin A- agarose, heparin-toyopearl® or Cibacrom blue 3GA Sepharose®; one or more steps involving hydrophobic interaction chromatography using such resins as phenyl ether, butyl ether, or propyl ether; or immunoaffinity chromatography.
  • the protein of the invention may also be expressed in a form which will facilitate purification.
  • it may be expressed as a fusion protein, such as those of maltose binding protein (MBP), glutathione-S-transferase (GST) or thioredoxin (TRX). Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively.
  • MBP maltose binding protein
  • GST glutathione-S-transferase
  • TRX thioredoxin
  • Kits for expression and purification of such fusion proteins are commercially available from New England BioLab (Beverly, MA), Pharmacia (Piscataway, NJ) and InVitrogen, respectively.
  • the protein can also be tagged with an epitope and subsequently purified by using a specific antibody directed to such epitope.
  • One such epitope (“Flag") is commercially available from Kod
  • RP- HPLC reverse-phase high performance liquid chromatography
  • hydrophobic RP-HPLC media e.g., silica gel having pendant methyl or other aliphatic groups
  • Some or all of the foregoing purification steps, in various combinations, can also be employed to provide a substantially homogeneous isolated recombinant protein.
  • the protein thus purified is substantially free of other mammalian proteins and is defined in accordance with the present invention as an "isolated protein.”
  • the protein of the invention may also be expressed as a product of transgenic animals, e.g., as a component of the milk of transgenic cows, goats, pigs, or sheep which are characterized by somatic or germ cells containing a nucleotide sequence encoding the protein.
  • the protein may also be produced by known conventional chemical synthesis.
  • the synthetically-constructed protein sequences by virtue of sharing primary, secondary or tertiary structural and/or conformational characteristics with proteins may possess biological properties in common therewith, including protein activity. Thus, they may be employed as biologically active or immunological substitutes for natural, purified proteins in screening of therapeutic compounds and in immunological processes for the development of antibodies
  • the proteins provided herein also include proteins characterized by amino acid sequences similar to those of pu ⁇ fied proteins but into which modification are naturally provided or deliberately engineered
  • modifications in the peptide or DNA sequences can be made by those skilled in the art using known techniques
  • Modifications of interest in the protein sequences may include the alteration, substitution, replacement, insertion or deletion of a selected amino acid residue in the coding sequence
  • one or more of the cysteine residues may be deleted or replaced with another amino acid to alter the conformation of the molecule
  • Techniques for such alteration, substitution, replacement, insertion or deletion are well known to those skilled in the art (see, e g , U S Patent No 4,518,584)
  • such alteration, substitution, replacement, insertion or deletion retains the desired activity of the protein
  • Other fragments and deovati ves of the sequences of proteins which would be expected to retain protein activity in whole or in part and may thus be useful for screening or other immunological methodologies may also be easily made by those skilled in the art given the disclosures herein
  • polynucleotides and proteins of the present invention are expected to exhibit one or more of the uses or biological activities (including those associated with assays cited herein) identified below Uses or activities descobed for proteins of the present invention may be provided by administration or use of such proteins or by administration or use of polynucleotides encoding such proteins (such as, for example, in gene therapies or vectors suitable for introduction of DNA)
  • the polynucleotides provided by the present invention can be used by the research community for va ⁇ ous purposes
  • the polynucleotides can be used to express recombinant protein for analysis, characte ⁇ zation or therapeutic use, as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in disease states), as molecular weight markers on Southern gels, as chromosome markers or tags (when labeled) to identify chromosomes or to map related gene positions; to compare with endogenous DNA sequences in patients to identify potential genetic disorders; as probes to hybridize and thus discover novel, related DNA sequences; as a source of information to derive PCR primers for genetic fingerprinting; as a probe to "subtract-out" known sequences in the process of discovering other novel polynucleotides; for selecting and making oligomers for attachment to a "gene chip” or other support, including for examination of expression patterns; to raise anti
  • the polynucleotide encodes a protein which binds or potentially binds to another protein (such as, for example, in a receptor-Iigand interaction)
  • the polynucleotide can also be used in interaction trap assays (such as, for example, that described in Gyuris et al., Cell 75:791 -803 (1993)) to identify polynucleotides encoding the other protein with which binding occurs or to identify inhibitors of the binding interaction.
  • the proteins provided by the present invention can similarly be used in assay to determine biological activity, including in a panel of multiple proteins for high-throughput screening; to raise antibodies or to elicit another immune response; as a reagent (including the labeled reagent) in assays designed to quantitatively determine levels of the protein (or its receptor) in biological fluids; as markers for tissues in which the corresponding protein is preferentially expressed (either constitutively or at a particular stage of tissue differentiation or development or in a disease state); and, of course, to isolate correlative receptors or ligands.
  • the protein binds or potentially binds to another protein (such as, for example, in a receptor-Iigand interaction)
  • the protein can be used to identify the other protein with which binding occurs or to identify inhibitors of the binding interaction. Proteins involved in these binding interactions can also be used to screen for peptide or small molecule inhibitors or agonists of the binding interaction. Any or all of these research utilities are capable of being developed into reagent grade or kit format for commercialization as research products.
  • Polynucleotides and proteins of the present invention can also be used as nutritional sources or supplements. Such uses include without limitation use as a protein or amino acid supplement, use as a carbon source, use as a nitrogen source and use as a source of carbohydrate In such cases the protein or polynucleotide of the invention can be added to the feed of a particular organism or can be administered as a separate solid or liquid preparation, such as in the form of powder, pills, solutions, suspensions or capsules In the case of microorganisms, the protein or polynucleotide of the invention can be added to the medium in or on which the microorganism is cultured
  • a protein of the present invention may exhibit cytokine, cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations.
  • cytokine cell proliferation (either inducing or inhibiting) or cell differentiation (either inducing or inhibiting) activity or may induce production of other cytokines in certain cell populations.
  • Many protein factors discovered to date, including all known cytokines have exhibited activity in one or more factor dependent cell proliferation assays, and hence the assays serve as a convenient confirmation of cytokine activity.
  • the activity of a protein of the present invention is evidenced by any one of a number of routine factor dependent cell proliferation assays for cell lines including, without limitation, 32D, DA2, DA1G, T10, B9, B9/1 1 , BaF3, MC9/G, M+ (preB M+), 2E8, RB5, DAI , 123, Tl 165, HT2, CTLL2, TF-1 , Mo7e and CMK
  • the activity of a protein of the invention may, among other means, be measured by the following methods Assays for T-cell or thymocyte proliferation include without limitation those descobed in * Current Protocols in Immunology, Ed by J. E Cohgan, A.M Kruisbeek, D H Marguhes, E.M Shevach, W Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 3, In Vitro assays for Mouse Lymphocyte Function 3.1 -3.19, Chapter 7, Immunologic studies in Humans); Takai et al., J. Immunol.
  • Assays for cytokine production and/or proliferation of spleen cells, lymph node cells or thymocytes include, without limitation, those desc ⁇ bed in * Polyclonal T cell stimulation, Kruisbeek, A.M. and Shevach, E.M. In Current Protocols in Immunology. J.E.e.a Coligan eds. Vol 1 pp. 3.12.1-3.12.14, John Wiley and Sons, Toronto 1994, and Measurement of mouse and human Interferon ⁇ , Schreiber, R.D. In Current Protocols in Immunology. J.E e.a Cohgan eds. Vol 1 pp. 6.8.1-6.8.8, John Wiley and Sons, Toronto. 1994.
  • Assays for proliferation and differentiation of hematopoietic and lymphopoietic cells include, without limitation, those described in: Measurement of Human and Mu ⁇ ne Interleukm 2 and Interleukin 4, Bottomly, K., Davis, L.S. and Lipsky, P.E. In Current Protocols in
  • Assays for T-cell clone responses to antigens include, without limitation, those described in: Current
  • a protein of the present invention may also exhibit immune stimulating or immune suppressing activity, including without limitation the activities for which assays are described herein.
  • a protein may be useful in the treatment of various immune deficiencies and disorders (including severe combined immunodeficiency (SOD)), e.g., in regulating (up or down) growth and proliferation of T and/or B lymphocytes, as well as effecting the cytolytic activity of NK cells and other cell populations.
  • SOD severe combined immunodeficiency
  • These immune deficiencies may be genetic or be caused by viral (e.g., HIV) as well as bacterial or fungal infections, or may result from autoimmune disorders.
  • infectious diseases causes by viral, bacterial, fungal or other infection may be treatable using a protein of the present invention, including infections by HIV, hepatitis viruses, herpesviruses, mycobacteria, Leishmania spp., malaria spp. and various fungal infections such as candidiasis.
  • a protein of the present invention may also be useful where a boost to the immune system generally may be desirable, i e , the treatment of cancer
  • Autoimmune disorders which may be treated using a protein of the present invention include, for example, connective tissue disease, multiple sclerosis, systemic lupus erythematosus, rheumatoid arthotis, autoimmune pulmonary inflammation, Guillain-Barre syndrome, autoimmune thyroiditis, insulin dependent diabetes mellitis, myasthenia gravis, graft-versus-host disease and autoimmune inflammatory eye disease
  • a protein of the present invention may also to be useful in the treatment of allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems
  • Other conditions, in which immune suppression is desired may also be treatable using a protein of the present invention
  • T cells may be inhibited by suppressing T cell responses or by inducing specific tolerance in T cells, or both Immunosuppression of T cell responses is generally an active, non-antigen-specific, process which requires continuous exposure of the T cells to the suppressive agent Tolerance, which involves inducing non-responsiveness or anergy in T cells, is distinguishable from immunosuppression in that it is generally antigen- specific and persists after exposure to the toleozing agent has ceased Operationally, tolerance can be demonstrated by the lack of a T cell response upon reexposure to specific antigen in the absence of the tolenzing agent
  • B lymphocyte antigen functions including without limitation B lymphocyte antigen functions (such as , for example, B7)
  • B lymphocyte antigen functions such as , for example, B7
  • GVHD graft-versus-host disease
  • blockage of T cell function should result in reduced tissue destruction in tissue transplantation
  • rejection of the transplant is initiated through its recognition as foreign by T cells, followed by an immune reaction that destroys the transplant
  • a molecule which inhibits or blocks interaction of a B7 lymphocyte antigen with its natural l ⁇ gand(s) on immune cells such as a soluble, monome ⁇ c form of a peptide having B7-2 activity alone or in conjunction with a monomeoc form of a peptide having an activity of another B lymphocyte antigen (e g , B7- 1 , B7-3) or blocking antibody)
  • poor to transplantation can lead to the binding of the molecule to
  • Blocking B lymphocyte antigen function in this matter prevents cytokine synthesis by immune cells, such as T cells, and thus acts as an immunosuppressant Moreover, the lack of costimulation may also be sufficient to anergize the T cells, thereby inducing tolerance in a subject Induction of long-term tolerance by B lymphocyte antigen-blocking reagents may avoid the necessity of repeated administration of these blocking reagents To achieve sufficient immunosuppression or tolerance in a subject, it may also be necessary to block the function of a combination of B lymphocyte antigens
  • the efficacy of particular blocking reagents in preventing organ transplant rejection or GVHD can be assessed using animal models that are predictive of efficacy in humans
  • appropriate systems which can be used include allogeneic cardiac grafts in rats and xenogeneic pancreatic islet cell grafts in mice, both of which have been used to examine the immunosuppressive effects of CTLA4Ig fusion proteins in vivo as descobed in Lenschow et al., Science 257.789-792 (1992) and Turka et al , Proc Natl. Acad. Sci USA, 89 1 1 102- 11 105 (1992).
  • mu ⁇ ne models of GVHD can be used to determine the effect of blocking B lymphocyte antigen function in vivo on the development of that disease
  • Blocking antigen function may also be therapeutical ly useful for treating autoimmune diseases.
  • Many autoimmune disorders are the result of inapprop ⁇ ate activation of T cells that are reactive against self tissue and which promote the production of cytokines and autoanti bodies involved in the pathology of the diseases
  • Preventing the activation of autoreactive T cells may reduce or eliminate disease symptoms
  • Administration of reagents which block costimulation of T cells by disrupting receptor * gand interactions of B lymphocyte antigens can be used to inhibit T cell activation and prevent production of autoanti bodies or T cell-deoved cytokines which may be involved in the disease process
  • blocking reagents may induce antigen-specific tolerance of autoreactive T cells which could lead to long-term relief from the disease
  • the efficacy of blocking reagents in preventing or alleviating autoimmune disorders can be determined using a number of well- characterized animal models of human autoimmune diseases.
  • Examples include mu ⁇ ne expe ⁇ mental autoimmune encephalitis, systemic lupus erythmatosis m MRUlpr/lpr mice or NZB hyb ⁇ d mice, mu ⁇ ne autoimmune collagen arth ⁇ tis, diabetes mel tus NOD mice and BB rats, and mu ⁇ ne expeomental myasthenia gravis (see Paul ed., Fundamental Immunology,
  • Upregulation of an antigen function (preferably a B lymphocyte antigen function), as a means of up regulating immune responses, may also be useful in therapy
  • Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response.
  • enhancing an immune response through stimulating B lymphocyte antigen function may be useful in cases of viral infection.
  • systemic viral diseases such as influenza, the common cold, and encephalitis might be alleviated by the administration of stimulatory fo ⁇ ns of B lymphocyte antigens systemically.
  • anti-viral immune responses may be enhanced in an infected patient by removing T cells from the patient, costimuiating the T cells in vitro with viral antigen-pulsed APCs either expressing a peptide of the present invention or together with a stimulatory form of a soluble peptide of the present invention and reintroducing the in vitro activated T cells into the patient.
  • Another method of enhancing anti-viral immune responses would be to isolate infected cells from a patient, transfect them with a nucleic acid encoding a protein of the present invention as described herein such that the cells express all or a portion of the protein on their surface, and reintroduce the transfected cells into the patient.
  • the infected cells would now be capable of delivering a costimulatory signal to, and thereby activate, T cells in vivo.
  • up regulation or enhancement of antigen function may be useful in the induction of tumor immunity.
  • Tumor cells e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma
  • a nucleic acid encoding at least one peptide of the present invention can be administered to a subject to overcome tumor-specific tolerance in the subject.
  • the tumor cell can be transfected to express a combination of peptides .
  • tumor cells obtained from a patient can be transfected ex vivo with an expression vector directing the expression of a peptide having B7-2-like activity alone, or in conjunction with a peptide having B7-l-like activity and/or B7-3-like activity.
  • the transfected tumor cells are returned to the patient to result in expression of the peptides on the surface of the transfected cell.
  • gene therapy techniques can be used to target a tumor cell for transfection in vivo.
  • tumor cells which lack MHC class I or MHC class II molecules, or which fail to reexpress sufficient amounts of MHC class I or MHC class II molecules, can be transfected with nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class 1 a chain protein and ⁇ 2 microglobulin protein or an MHC class II a chain protein and an MHC class II ⁇ chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • nucleic acid encoding all or a portion of (e.g., a cytoplasmic-domain truncated portion) of an MHC class 1 a chain protein and ⁇ 2 microglobulin protein or an MHC class II a chain protein and an MHC class II ⁇ chain protein to thereby express MHC class I or MHC class II proteins on the cell surface.
  • a gene encoding an antisense construct which blocks expression of an MHC class II associated protein, such as the inva ⁇ ant chain can also be cotransfected with a DNA encoding a peptide having the activity of a B lymphocyte antigen to promote presentation of tumor associated antigens and induce tumor specific immunity
  • a T cell mediated immune response in a human subject may be sufficient to overcome tumor-specific tolerance in the subject
  • the activity of a protein of the invention may, among other means, be measured by the following methods.
  • Suitable assays for thymocyte or splenocyte cytotoxicity include, without limitation, those described in Current Protocols in Immunology, Ed by J E Co gan, A M. Kruisbeek, D.H. Margulies, E.M. Shevach, W Strober, Pub.
  • Assays for T-cell -dependent immunoglobulin responses and isotype switching include, without limitation, those desc ⁇ bed in * Ma szewski, J Immunol. 144.3028-3033, 1990; and Assays for B cell function.
  • Assays for B cell function include, without limitation, those desc ⁇ bed in * Ma szewski, J Immunol. 144.3028-3033, 1990; and Assays for B cell function.
  • MLR Mixed lymphocyte reaction
  • Dend ⁇ tic cell-dependent assays (which will identify, among others, proteins expressed by dendritic cells that activate naive T-cells) include, without limitation, those described in. Guery et al., J. Immunol. 134:536-544, 1995; Inaba et al., Journal of Expe ⁇ mental Medicine 173:549-559, 1991 ; Macatonia et al., Journal of Immunology 154:5071-5079, 1995; Porgador et al., Journal of Experimental Medicine 182:255-260, 1995; Nair et al., Journal of Virology 67:4062-4069, 1993; Huang et al., Science 264:961 -965, 1994; Macatonia et al., Journal of Experimental Medicine 169: 1255-1264, 1989; Bhardwaj et al., Journal of Clinical Investigation 94:797-807, 1994; and Inab et al., Journal of Experimental Medicine 172:631 - 640
  • lymphocyte survival/apoptosis (which will identify, among others, proteins that prevent apoptosis after superantigen induction and proteins that regulate lymphocyte homeostasis) include, without limitation, those described in: Darzynkiewicz et al., Cytometry 13:795-808, 1992; Gorczyca et al., Leukemia 7:659-670, 1993; Gorczyca et al., Cancer Research 53: 1945-1951 , 1993; Itoh et al..
  • Assays for proteins that influence early steps of T-cell commitment and development include, without limitation, those described in: Antica et al.. Blood 84: 1 1 1-1 17, 1994; Fine et al., Cellular Immunology 155: 1 1 1 -122, 1994; Galy et al., Blood 85:2770-2778, 1995; Toki et al., Proc. Nat. Acad Sci. USA 88:7548-7551 , 1991.
  • a protein of the present invention may be useful in regulation of hematopoiesis and, consequently, in the treatment of myeloid or lymphoid cell deficiencies. Even marginal biological activity in support of colony forming cells or of factor-dependent cell lines indicates involvement in regulating hematopoiesis, e.g.
  • erythroid progenitor cells in supporting the growth and proliferation of erythroid progenitor cells alone or in combination with other cytokines, thereby indicating utility, for example, in treating various anemias or for use in conjunction with irradiation/chemotherapy to stimulate the production of erythroid precursors and/or erythroid cells; in supporting the growth and proliferation of myeloid cells such as granulocytes and monocytes/macrophages (i.e., traditional CSF activity) useful, for example, in conjunction with chemotherapy to prevent or treat consequent myelo-suppression; in supporting the growth and proliferation of megakaryocytes and consequently of platelets thereby allowing prevention or treatment of various platelet disorders such as thrombocytopenia, and generally for use in place of or complimentary to platelet transfusions; and/or in supporting the growth and proliferation of hematopoietic stem cells which are capable of maturing to any and all of the above- mentioned hematopoietic cells and therefore find therapeutic utility in various stem cell disorders
  • Assays for embryonic stem cell differentiation include, without limitation, those described in: Johansson et al. Cellular Biology 15: 141 -151 , 1995; Keller et al., Molecular and Cellular Biology 13:473-486, 1993; McClanahan et al., Blood 81 :2903-2915, 1993.
  • Assays for stem cell survival and differentiation include, without limitation, those described in: Methylcellulose colony forming assays, Freshney, M.G. In Culture of Hematopoietic Cells. R.I. Freshney, et al. eds. Vol pp. 265-268, Wiley-Liss, Inc., New York, NY. 1994; Hirayama et al., Proc. Natl. Acad. Sci. USA 89:5907-5911, 1992; Primitive hematopoietic colony forming cells with high proliferative potential, McNiece, I.K. and Briddell, R.A.
  • a protein of the present invention also may have utility in compositions used for bone, cartilage, tendon, ligament and/or nerve tissue growth or regeneration, as well as for wound healing and tissue repair and replacement, and in the treatment of burns, incisions and ulcers.
  • a protein of the present invention which induces cartilage and/or bone growth in circumstances where bone is not normally formed, has application in the healing of bone fractures and cartilage damage or defects in humans and other animals.
  • Such a preparation employing a protein of the invention may have prophylactic use in closed as well as open fracture reduction and also in the improved fixation of artificial joints De novo bone formation induced by an osteoge c agent cont ⁇ butes to the repair of congenital, trauma induced, or oncologic resection induced craniofacial defects, and also is useful in cosmetic plastic surgery
  • a protein of this invention may also be used in the treatment of pe ⁇ odontdl disease, and in other tooth repair processes
  • Such agents may provide an environment to attract bone- forming cells, stimulate growth of bone-forming cells or induce differentiation of progenitors of bone-forming cells
  • a protein of the invention may also be useful in the treatment of osteoporosis or osteoarth ⁇ tis, such as through stimulation of bone and/or cartilage repair or by blocking inflammation or processes of tissue destruction (
  • tissue regeneration activity that may be attobutable to the protein of the present invention is tendon/ligament formation
  • a protein of the present invention which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals
  • Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repaiong defects to tendon or ligament tissue
  • De novo tendon/ligament-like tissue formation induced by a composition of the present invention contobutes to the repair of congenital, trauma induced, or other tendon or ligament defects of other oogin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments
  • the compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells,
  • the protein of the present invention may also be useful for proliferation of neural cells and for regeneration of nerve and brain tissue, i e for the treatment of central and pe ⁇ pheral nervous system diseases and neuropathies, as well as mechanical and traumatic disorders, which involve degeneration, death or trauma to neural cells or nerve tissue More specifically, a protein may be used in the treatment of diseases of the pe ⁇ pheral nervous system, such as peripheral nerve injuries, peripheral neuropathy and localized neuropathies, and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome. Further conditions which may be treated in accordance with the present invention include mechanical and traumatic disorders, such as spinal cord disorders, head trauma and cerebrovascular diseases such as stroke. Peripheral neuropathies resulting from chemotherapy or other medical therapies may also be treatable using a protein of the invention.
  • Proteins of the invention may also be useful to promote better or faster closure of non- healing wounds, including without limitation pressure ulcers, ulcers associated with vascular insufficiency, surgical and traumatic wounds, and the like.
  • a protein of the present invention may also exhibit activity for generation or regeneration of other tissues, such as organs (including, for example, pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac) and vascular (including vascular endothelium) tissue, or for promoting the growth of cells comprising such tissues.
  • organs including, for example, pancreas, liver, intestine, kidney, skin, endothelium
  • muscle smooth, skeletal or cardiac
  • vascular including vascular endothelium
  • a protein of the present invention may also be useful for gut protection or regeneration and treatment of lung or liver fibrosis, reperfusion injury in various tissues, and conditions resulting from systemic cytokine damage.
  • a protein of the present invention may also be useful for promoting or inhibiting differentiation of tissues described above from precursor tissues or cells; or for inhibiting the growth of tissues described above.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for tissue generation activity include, without limitation, those described in: International Patent Publication No. WO95/16035 (bone, cartilage, tendon); International Patent Publication No. WO95/05846 (nerve, neuronal); International Patent Publication No. WO91/07491 (skin, endothelium ).
  • Assays for wound healing activity include, without limitation, those described in:
  • a protein of the present invention may also exhibit activin- or inhibin-related activities. Inhibins are characterized by their ability to inhibit the release of follicle stimulating hormone (FSH), while activins and are characterized by their ability to stimulate the release of follicle stimulating hormone (FSH). Thus, a protein of the present invention, alone or in heterodimers with a member of the inhibin ⁇ family, may be useful as a contraceptive based on the ability of inhibins to decrease fertility in female mammals and decrease spermatogenesis in male mammals. Administration of sufficient amounts of other inhibins can induce infertility in these mammals.
  • FSH follicle stimulating hormone
  • the protein of the invention may be useful as a fertility inducing therapeutic, based upon the ability of activin molecules in stimulating FSH release from cells of the anterior pituitary. See, for example, United States Patent 4,798,885.
  • a protein of the invention may also be useful for advancement of the onset of fertility in sexually immature mammals, so as to increase the lifetime reproductive performance of domestic animals such as cows, sheep and pigs.
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assays for activin/inhibin activity include, without limitation, those described in: Vale et al.. Endocrinology 91 :562-572, 1972; Ling et al., Nature 321 :779-782, 1986; Vale et al., Nature 321 :776-779, 1986; Mason et al., Nature 318:659-663, 1985; Forage et al., Proc. Natl. Acad. Sci. USA 83:3091 -3095, 1986.
  • a protein of the present invention may have chemotactic or chemokinetic activity (e.g., act as a chemokine) for mammalian cells, including, for example, monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells.
  • Chemotactic and chemokinetic proteins can be used to mobilize or attract a desired cell population to a desired site of action.
  • Chemotactic or chemokinetic proteins provide particular advantages in treatment of wounds and other trauma to tissues, as well as in treatment of localized infections. For example, attraction of lymphocytes, monocytes or neutrophils to tumors or sites of infection may result in improved immune responses against the tumor or infecting agent.
  • a protein or peptide has chemotactic activity for a particular cell population if it can stimulate, directly or indirectly, the directed orientation or movement of such cell population.
  • the protein or peptide has the ability to directly stimulate directed movement of cells. Whether a particular protein has chemotactic activity for a population of cells can be readily determined by employing such protein or peptide in any known assay for cell chemotaxis.
  • the activity of a protein of the invention may, among other means, be measured by the following methods: Assays for chemotactic activity (which will identify proteins that induce or prevent chemotaxis) consist of assays that measure the ability of a protein to induce the migration of cells across a membrane as well as the ability of a protein to induce the adhesion of one cell population to another cell population. Suitable assays for movement and adhesion include, without limitation, those described m: Current Protocols in Immunology, Ed by J.E Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.
  • a protein of the invention may also exhibit hemostatic or thrombolytic activity As a result, such a protein is expected to be useful in treatment of vaoous coagulation disorders (including hereditary disorders, such as hemophilias) or to enhance coagulation and other hemostatic events in treating wounds resulting from trauma, surgery or other causes
  • a protein of the invention may also be useful for dissolving or inhibiting formation of thromboses and for treatment and prevention of conditions resulting therefrom (such as, for example, infarction of cardiac and central nervous system vessels (e.g., stroke).
  • the activity of a protein of the invention may, among other means, be measured by the following methods:
  • Assay for hemostatic and thrombolytic activity include, without limitation, those described in: Linet et al., J. Clin. Pharmacol. 26: 131-140, 1986; Burdick et al., Thrombosis Res. 45:413-419, 1987; Humphrey et al., Fibnnolysis 5:71-79 (1991 ); Schaub, Prostaglandins 35:467-474, 1988.
  • a protein of the present invention may also demonstrate activity as receptors, receptor ligands or inhibitors or agonists of receptor/ligand interactions.
  • receptors and ligands include, without limitation, cytokine receptors and their ligands, receptor kinases and their ligands, receptor phosphatases and their ligands, receptors involved in cell-cell interactions and their ligands (including without limitation, cellular adhesion molecules (such as selectins, integrins and their ligands) and receptor/ligand pairs involved in antigen presentation, antigen recognition and development of cellular and humoral immune responses).
  • Receptors and ligands are also useful for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interaction.
  • a protein of the present invention may themselves be useful as inhibitors of receptor/ligand interactions.
  • Suitable assays for receptor-Iigand activity include without limitation those described in:Current Protocols in Immunology, Ed by J.E. Coligan, A.M. Kruisbeek, D.H. Margulies, E.M. Shevach, W.Strober, Pub. Greene Publishing Associates and Wiley-Interscience (Chapter 7.28, Measurement of Cellular Adhesion under static conditions 7.28.1 -7.28.22), Takai et al., Proc. Natl. Acad. Sci. USA 84:6864-6868, 1987; Bierer et al., J. Exp. Med.
  • Proteins of the present invention may also exhibit anti-inflammatory activity.
  • the anti- inflammatory activity may be achieved by providing a stimulus to cells involved in the inflammatory response, by inhibiting or promoting cell-cell interactions (such as, for example, cell adhesion), by inhibiting or promoting chemotaxis of cells involved in the inflammatory process, inhibiting or promoting cell extravasation, or by stimulating or suppressing production of other factors which more directly inhibit or promote an inflammatory response.
  • Proteins exhibiting such activities can be used to treat inflammatory conditions including chronic or acute conditions), including without limitation inflammation associated with infection (such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)), ischemia- reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or che okine-induced lung injury, inflammatory bowel disease, Crohn's disease or resulting from over production of cytokines such as TNF or IL-1. Proteins of the invention may also be useful to treat anaphylaxis and hypersensitivity to an antigenic substance or material.
  • infection such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)
  • ischemia- reperfusion injury such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)
  • ischemia- reperfusion injury such as septic shock, sepsis or systemic inflammatory response syndrome (SIRS)
  • a protein of the invention may exhibit other anti-tumor activities
  • a protein may inhibit tumor growth directly or indirectly (such as, for example, via ADCC)
  • a protein may exhibit its tumor inhibitory activity by acting on tumor tissue or tumor precursor tissue, by inhibiting formation of tissues necessary to support tumor growth (such as, for example, by inhibiting angiogenesis), by causing production of other factors, agents or cell types which inhibit tumor growth, or by suppressing, eliminating or inhibiting factors, agents or cell types which promote tumor growth
  • a protein of the invention may also exhibit one or more of the following additional activities or effects inhibiting the growth, infection or function of, or killing, infectious agents, including, without limitation, bacte ⁇ a, viruses, fungi and other parasites, effecting (suppressing or enhancing) bodily characte ⁇ stics, including, without limitation, height, weight, hair color, eye color, skin, fat to lean ratio or other tissue pigmentation, or organ or body part size or shape (such as, for example, breast augmentation or diminution, change in bone form or shape), effecting biorhythms or ca ⁇ cadic cycles or rhythms, effecting the fertility of male or female subjects; effecting the metabolism, catabolism, anabolis , processing, utilization, storage or elimination of dietary fat, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutotional factors or component(s), effecting behavioral characteostics, including, without limitation, appetite, libido, stress, cognition (including cognitive disorders), depression (including depressive disorders
  • a protein of the present invention may be used in a pharmaceutical composition when combined with a pharmaceutically acceptable carrier.
  • a pharmaceutically acceptable carrier may also contain (in addition to protein and a carrier) diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.
  • pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier will depend on the route of administration.
  • the pharmaceutical composition of the invention may also contain cytokines, lymphokines, or other hematopoietic factors such as M-CSF, GM-CSF, TNF, IL-1 , IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-1 1 , IL-12, IL-13, EL-14, IL-15, IFN, TNFO, TNFT, TNF2, G-CSF, Meg-CSF, thrombopoietin, stem cell factor, and erythropoietin.
  • the pharmaceutical composition may further contain other agents which either enhance the activity of the protein or compliment its activity or use in treatment.
  • protein of the present invention may be included in formulations of the particular cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent to minimize side effects of the cytokine, lymphokine, other hematopoietic factor, thrombolytic or anti-thrombotic factor, or anti-inflammatory agent.
  • a protein of the present invention may be active in multimers (e.g., heterodimers or homodimers) or complexes with itself or other proteins.
  • pharmaceutical compositions of the invention may comprise a protein of the invention in such multimeric or complexed form.
  • the pharmaceutical composition of the invention may be in the form of a complex of the protein(s) of present invention along with protein or peptide antigens.
  • the protein and/or peptide antigen will deliver a stimulatory signal to both B and T lymphocytes.
  • B lymphocytes will respond to antigen through their surface immunoglobulin receptor.
  • T lymphocytes will respond to antigen through the T cell receptor (TCR) following presentation of the antigen by MHC proteins.
  • TCR T cell receptor
  • MHC and structurally related proteins including those encoded by class I and class II MHC genes on host cells will serve to present the peptide antigen(s) to T lymphocytes.
  • the antigen components could also be supplied as purified MHC-peptide complexes alone or with co-stimulatory molecules that can directly signal T cells.
  • antibodies able to bind surface immunolgobulin and other molecules on B cells as well as antibodies able to bind the TCR and other molecules on T cells can be combined with the pharmaceutical composition of the invention.
  • the pharmaceutical composition of the invention may be in the form of a liposome in which protein of the present invention is combined, in addition to other pharmaceutically acceptable earners, with amphipathic agents such as pids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers in aqueous solution
  • Suitable hpids for liposomal formulation include, without limitation, monoglyce ⁇ des, diglyce ⁇ des, sulfatides, lysolecithin, phosphohpids, saponin, bile acids, and the like
  • Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U S Patent No 4,235,871 , U S Patent No 4,501,728, U S Patent No 4,837,028, and U S Patent No 4,737,323, all of which are incorporated herein by reference
  • the term "therapeutical ly effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, l e , treatment, healing, prevention or amelioration of the relevant medical condition, or an increase in rate of treatment, healing, prevention or amelioration of such conditions
  • the term refers to that ingredient alone
  • the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered in combination, se ⁇ ally or simultaneously
  • a therapeutically effective amount of protein of the present invention is administered to a mammal having a condition to be treated.
  • Protein of the present invention may be administered in accordance with the method of the invention either alone or in combination with other therapies such as treatments employing cytokines, lymphokines or other hematopoietic factors
  • protein of the present invention may be administered either simultaneously with the cytok ⁇ ne(s), iymphok ⁇ ne(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors, or sequentially.
  • the attending physician will decide on the approp ⁇ ate sequence of administe ⁇ ng protein of the present invention in combination with cytokme(s), lymphok ⁇ ne(s), other hematopoietic factor(s), thrombolytic or anti-thrombotic factors
  • Administration of protein of the present invention used in the pharmaceutical composition or to practice the method of the present invention can be earned out in a va ⁇ ety of conventional ways, such as oral mgestion, inhalation, topical application or cutaneous, subcutaneous, mtrape ⁇ toneal, parenteral or intravenous injection Intravenous administration to the patient is preferred.
  • protein of the present invention When administered orally, protein of the present invention will be in the form of a tablet, capsule, powder, solution or elixir
  • the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant
  • the tablet, capsule, and powder contain from about 5 to 95% protein of the present invention, and preferably from about 25 to 90% protein of the present invention
  • a liquid earner such as water, petroleum, oils of animal or plant o ⁇ gin such as peanut oil, mineral oil, soybean oil, or sesame oil, or synthetic oils
  • the liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccha ⁇ de solution, or glycols such as ethylene glycoi, propylene glycol or polyethylene glycol
  • the pharmaceutical composition contains from about 0 5 to 90% by weight of protein of the present invention, and preferably from about 1 to 50% protein of the present invention
  • protein of the present invention When a therapeutically effective amount of protein of the present invention is administered by intravenous, cutaneous or subcutaneous injection, protein of the present invention will be in the form of a pyrogen-free, parenterally acceptable aqueous solution
  • a preferred pharmaceutical composition for intravenous, cutaneous, or subcutaneous injection should contain, in addition to protein of the present invention, an isotonic vehicle such as Sodium Chlo ⁇ de Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chlo ⁇ de Injection, Lactated Ringers Injection, or other vehicle as known in the art
  • the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art
  • the amount of protein of the present invention in the pharmaceutical composition of the present invention will depend upon the nature and seventy of the condition being treated, and on the nature of p ⁇ or treatments which the patient has undergone Ultimately, the attending physician will decide the amount of protein of the present invention with which to treat each individual patient Initially, the attending physician will administer low doses of protein of the present invention and observe the patient's response Larger doses of protein of the present invention may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further It is contemplated that the vanous pharmaceutical compositions used to practice the method of the present invention should contain about 001 ⁇ g to about 100 mg (preferably about 0 l ⁇ g to about 10 mg, more preferably about 0 1 ⁇ g to about 1 mg) of protein of the present invention per kg body weight
  • the duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the seventy of the disease being treated and the condition and potential idiosyncratic response of each individual patient It is contemplated that the duration of each application of the protein of the present invention will be in the range of 12 to 24 hours of continuous intravenous administration Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention
  • Protein of the invention may also be used to immunize animals to obtain polyclonal and monoclonal antibodies which specifically react with the protein Such antibodies may be obtained using either the entire protein or fragments thereof as an immunogen
  • the peptide immunogens additionally may contain a cysteine residue at the carboxyl terminus, and are conjugated to a hapten such as keyhole limpet hemocyanin (KLH) Methods for synthesizing such peptides are known in the art, for example, as in R P Mernfield, J Amer Chem.Soc 85.
  • Monoclonal antibodies binding to the protein of the invention may be useful diagnostic agents for the immunodetection of the protein
  • Neutralizing monoclonal antibodies binding to the protein may also be useful therapeutics for both conditions associated with the protein and also in the treatment of some forms of cancer where abnormal expression of the protein is involved
  • neutralizing monoclonal antibodies against the protein may be useful in detecting and preventing the metastatic spread of the cancerous cells, which may be mediated by the protein
  • the therapeutic method includes administering the composition topically, systematically, or locally as an implant or device
  • the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form
  • the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of bone, cartilage or tissue damage
  • Topical administration may be suitable for wound healing and tissue repair
  • Therapeutically useful agents other than a protein of the invention which may also optionally be included in the composition as descnbed above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention
  • the composition would include a mat ⁇ x capable of de ve ⁇ ng the protein-containing composition to the site of bone and/or cartilage damage, providing a structure for the developing bone and cartilage and optimally capable of being resorbed into the body.
  • Such mat ⁇ ces may be formed of mate ⁇ als
  • compositions may be biodegradable and chemically defined calcium sulfate, tricalciumphosphate, hydroxyapatite, polylactic acid, polyglycolic acid and polyanhydrides.
  • Other potential materials are biodegradable and biologically well-defined, such as bone or dermal collagen.
  • Further matrices are comprised of pure proteins or extracellular matrix components.
  • Other potential matrices are nonbiodegradable and chemically defined, such as sintered hydroxapatite, bioglass, aluminates, or other ceramics.
  • Matrices may be comprised of combinations of any of the above mentioned types of material, such as polylactic acid and hydroxyapatite or collagen and tricalciumphosphate.
  • the bioceramics may be altered in composition, such as in calcium-aluminate-phosphate and processing to alter pore size, particle size, particle shape, and biodegradability.
  • a 50:50 (mole weight) copolymer of lactic acid and glycolic acid in the form of porous particles having diameters ranging from 150 to 800 microns.
  • a sequestering agent such as carboxymethyl cellulose or autologous blood clot, to prevent the protein compositions from disassociating from the matrix.
  • a preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl-methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC).
  • CMC carboxymethylcellulose
  • Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene glycol), polyoxyethylene oxide, carboxyvinyl polymer and poly( vinyl alcohol).
  • the amount of sequestering agent useful herein is 0.5-20 wt%, preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the osteogenic activity of the progenitor cells.
  • proteins of the invention may be combined with other agents beneficial to the treatment of the bone and/or cartilage defect, wound, or tissue in question.
  • agents include various growth factors such as epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factors (TGF- ⁇ and TGF- ⁇ ), and insulinlike growth factor (IGF).
  • EGF epidermal growth factor
  • PDGF platelet derived growth factor
  • TGF- ⁇ and TGF- ⁇ transforming growth factors
  • IGF insulinlike growth factor
  • the therapeutic compositions are also presently valuable for veterinary applications. Particularly domestic animals and thoroughbred horses, in addition to humans, are desired patients for such treatment with proteins of the present invention.
  • the dosage regimen of a protein-containing pharmaceutical composition to be used in tissue regeneration will be determined by the attending physician consideong vanous factors which modify the action of the proteins, e g , amount of tissue weight desired to be formed, the site of damage, the condition of the damaged tissue, the size of a wound, type of damaged tissue (e g , bone), the patient's age, sex, and diet, the severity of any infection, time of administration and other clinical factors
  • the dosage may vary with the type of mat ⁇ x used in the reconstitution and with inclusion of other proteins in the pharmaceutical composition
  • the addition of other known growth factors, such as IGF I (insulin like growth factor I) may also effect the dosage Progress can be monitored by periodic assessment of tissue/bone growth and/or repair, for example, X-rays, histomorphometnc determinations and tetracyclme label
  • Polynucleotides of the present invention can also be used for gene therapy Such polynucleotides can be introduced either in vivo or ex vivo into cells for expression in a mammalian subject Polynucleotides of the invention may also be administered by other known methods for introduction of nucleic acid into a cell or organism (including, without limitation, in the form of viral vectors or naked DNA)
  • AAAGTGAGAG AACTTAATTA TTTGCAAAGG TAAGTTACAG CTTGTTTTTTTT GAGAGAATCA 180
  • GAGAACTCGG TTTGGTAGAC TTGGACATCT CTCTGGCTTC TGAANANCCT GAAGCTGGCC 60
  • MOLECULE TYPE cDNA (xi ) SEQUENCE DESCRIPTION SEQ ID NO 10
  • AAACATTTCC AAACCACTAC AGTATTGTGA CAGGCTTGTA TGAAGAAAGC CATGGCATTG 480
  • MOLECULE TYPE protein
  • SEQUENCE DESCRIPTION SEQ ID NO : 12 :
  • ACGTGCTCCG CAGCGATGGG AAGACGTGTG CAAAATTGGA CTCTTGTGCT CTGGGGGACC 480
  • CTGTAGGGAC CACTTTGGAT GGAGAGAGTA TCCCGAGTNT GTCATTNGAT TGATTGAAGA 60

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne de nouveaux polynucléotides et les protéines codées par ces derniers.
PCT/US1997/014641 1996-08-23 1997-08-20 Proteines secretees et polynucleotides les codant WO1998007855A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP10510922A JP2000516816A (ja) 1996-08-23 1997-08-20 分泌蛋白およびそれらをコードするポリヌクレオチド
EP97937331A EP0922100A2 (fr) 1996-08-23 1997-08-20 Proteines secretees et polynucleotides les codant
CA002263192A CA2263192A1 (fr) 1996-08-23 1997-08-20 Proteines secretees et polynucleotides les codant
AU39864/97A AU3986497A (en) 1996-08-23 1997-08-20 Secreted proteins and polynucleotides encoding them

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70193196A 1996-08-23 1996-08-23
US08/701,931 1996-08-23

Publications (2)

Publication Number Publication Date
WO1998007855A2 true WO1998007855A2 (fr) 1998-02-26
WO1998007855A3 WO1998007855A3 (fr) 1998-05-07

Family

ID=24819253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/014641 WO1998007855A2 (fr) 1996-08-23 1997-08-20 Proteines secretees et polynucleotides les codant

Country Status (5)

Country Link
EP (1) EP0922100A2 (fr)
JP (1) JP2000516816A (fr)
AU (1) AU3986497A (fr)
CA (1) CA2263192A1 (fr)
WO (1) WO1998007855A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004002A1 (fr) * 1997-07-21 1999-01-28 Incyte Pharmaceuticals, Inc. Matriline-3 humaine
EP1032652A1 (fr) * 1997-11-21 2000-09-06 Genetics Institute, Inc. Proteines secretees et polynucleotides codant ces proteines
EP1627886A1 (fr) * 1997-10-07 2006-02-22 Ono Pharmaceutical Co., Ltd. Polypeptides, ADNc le codant et leur utilisation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005780A1 (fr) * 1988-11-18 1990-05-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Recepteurs de dopamine et genes
WO1990014432A1 (fr) * 1989-05-23 1990-11-29 Genetics Institute, Inc. Une cytokine humaine, l'interleukine 9
EP0510691A1 (fr) * 1991-04-26 1992-10-28 Osaka Bioscience Institute ADN codant un antigène de surface cellulaire humaine
WO1994007916A1 (fr) * 1992-10-07 1994-04-14 Merck & Co., Inc. Recepteur d'hormone steroide humain neri
WO1996017925A1 (fr) * 1994-12-06 1996-06-13 Immunex Corporation Cytokine designee par lerk-7
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1997007198A2 (fr) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Sequences d'adn et proteines secretees codees par celles-ci
WO1997025427A1 (fr) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mpc-2)

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005780A1 (fr) * 1988-11-18 1990-05-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Recepteurs de dopamine et genes
WO1990014432A1 (fr) * 1989-05-23 1990-11-29 Genetics Institute, Inc. Une cytokine humaine, l'interleukine 9
EP0510691A1 (fr) * 1991-04-26 1992-10-28 Osaka Bioscience Institute ADN codant un antigène de surface cellulaire humaine
WO1994007916A1 (fr) * 1992-10-07 1994-04-14 Merck & Co., Inc. Recepteur d'hormone steroide humain neri
US5536637A (en) * 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
WO1996017925A1 (fr) * 1994-12-06 1996-06-13 Immunex Corporation Cytokine designee par lerk-7
WO1997007198A2 (fr) * 1995-08-11 1997-02-27 Genetics Institute, Inc. Sequences d'adn et proteines secretees codees par celles-ci
WO1997025427A1 (fr) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mpc-2)

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADAMS M D ET AL: "3,400 NEW EXPRESSED SEQUENCE TAGS IDENTIFY DIVERSITY OF TRANSCRIPTS IN HUMAN BRAIN" NATURE GENETICS, vol. 4, no. 3, pages 256-267, XP000611495 *
JACOBS K ET AL: "A novel method for isolating eukaryotic cDNA clones encoding secreted proteins." KEYSTONE SYMPOSIUM ON DENDRITIC CELLS: ANTIGEN PRESENTING CELLS OF T AND B LYMPHOCYTES, TAOS, NEW MEXICO, USA, MARCH 10-16, 1995. JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT 0 (21A). 1995. 19. ISSN: 0733-1959, XP002027246 *
L. HILLIER ET AL.: "y172e10.s1 Homo sapiens cDNA clone 43276 3'" EMBL SEQUENCE DATABASE, 23 June 1995, HEIDELBERG, BRD, XP002049381 cited in the application *
L. HILLIER ET AL.: "zd84d09.r1 Soares fetal heart NbHH19W Homo sapiens cDNA clone 347345 5'" EMBL SEQUENCE DATABASE, 27 June 1996, HEIDELBERG, BRD, XP002049380 cited in the application *
R.J. KAUFMAN ET AL.: "Effect of von Willebrand factor coexpression on the synthesis and secretion of factor VIII in chinese hamster ovary cells" MOL. CELL. BIOL., vol. 9, no. 3, March 1989, ASM WASHINGTON, DC,US, pages 1233-1242, XP002041592 *
R.J. KAUFMAN ET AL.: "Improved vectors for stable expression of foreign genes in mammalian cells by use of the untranslated leader sequence from EMC virus" NUCLEIC ACIDS RESEARCH, vol. 19, no. 16, 1991, IRL PRESS LIMITED,OXFORD,ENGLAND, pages 4485-4490, XP002041594 cited in the application *
R.J. KAUFMAN ET AL.: "The phosphorylation state of eucaryotic initiation factor 2 alters translation efficiency of specific mRNAs" MOL. CELL. BIOL., vol. 9, no. 3, March 1989, ASM WASHINGTON, DC,US, pages 946-958, XP002041593 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999004002A1 (fr) * 1997-07-21 1999-01-28 Incyte Pharmaceuticals, Inc. Matriline-3 humaine
EP1627886A1 (fr) * 1997-10-07 2006-02-22 Ono Pharmaceutical Co., Ltd. Polypeptides, ADNc le codant et leur utilisation
US7189546B2 (en) 1997-10-07 2007-03-13 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same, and use of them
US7638281B2 (en) 1997-10-07 2009-12-29 Ono Pharmaceutical Co., Ltd. Polypeptide, cDNA encoding the same and use of them
EP1032652A1 (fr) * 1997-11-21 2000-09-06 Genetics Institute, Inc. Proteines secretees et polynucleotides codant ces proteines
EP1032652A4 (fr) * 1997-11-21 2002-12-04 Inst Genetics Llc Proteines secretees et polynucleotides codant ces proteines

Also Published As

Publication number Publication date
AU3986497A (en) 1998-03-06
CA2263192A1 (fr) 1998-02-26
EP0922100A2 (fr) 1999-06-16
JP2000516816A (ja) 2000-12-19
WO1998007855A3 (fr) 1998-05-07

Similar Documents

Publication Publication Date Title
US5723315A (en) Secreted proteins and polynucleotides encoding them
US5965693A (en) Secreted proteins and polynucleotides encoding them
US5708157A (en) Secreted proteins and polynucleotides encoding them
US5728819A (en) Secreted proteins and polynucleotides encoding them
US5807709A (en) Secreted proteins and polynucleotides encoding them
US5837490A (en) Secreted proteins and polynucleotides encoding them
US5831056A (en) Secreted proteins and polynucleotides encoding them
US5827688A (en) Secreted proteins and polynucleotides encoding them
EP0954577A2 (fr) Proteines secretees et polynucleotides les codant
WO1998007855A2 (fr) Proteines secretees et polynucleotides les codant
WO1998001553A2 (fr) Proteines secretees et polynucleotides codant lesdites proteines
WO1998001552A2 (fr) Proteines secretees et polynucleotides codant lesdites proteines
WO1998007856A1 (fr) Proteines secretees et polynucleotides codant pour ces proteines
WO1997048798A1 (fr) Polynucleotide codant une proteine secretee isolee dans des cellules dendritiques humaines
EP0970108A2 (fr) Proteines secretees et polynucleotides les codant
EP0950101A1 (fr) Proteines secretees et polynucleotides codant pour elles
WO1998004695A1 (fr) Proteines secretees et polynucleotides les codant
EP0937143A2 (fr) Proteines secretees et polynucleotides les codant
WO1998004696A1 (fr) Proteines secretees et polynucleotides les codant
WO1998020125A1 (fr) Proteines secretees et polynucleotides qui les codent
WO1998014575A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP0912606A2 (fr) Proteines secretees et polynucleotides les codant
WO1998001469A2 (fr) Proteines secretees et polynucleotides les codant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase in:

Ref document number: 2263192

Country of ref document: CA

Ref country code: CA

Ref document number: 2263192

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 1998 510922

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997937331

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1997937331

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1997937331

Country of ref document: EP